Concurrently, a validation study in bladder cancer based on MHC-II pathway expression confirmed that the MHC-II pathway exhibits higher predictive efficacy for anti-PD-L1 immunotherapy response than tumor mutation burden (TME) [35]. This evidence concerns the gene CD274 and neoplasm.